Medtronic plc (MDT) CEO Discloses the Impacts of Tariffs on the Company

Medtronic plc (NYSE:MDT) is one of the 10 Best Brain-Computer Interface Stocks to Buy.

On June 8, Medtronic plc (NYSE:MDT) Chairman and CEO Geoffrey Martha said on Fox Business Network's The Claman Countdown that the company now expects a $250 million tariff hit for fiscal 2027, down from a prior $300 million estimate due to supply chain adjustments. It includes $75 million in the first quarter.

Martha noted the figure could change given new US tariff threats targeting multiple trading partners emerge, saying, "we'll have to re-evaluate that."

He said tariffs remain "pretty meaningful," surging year over year and adding pressure along with higher input costs such as fuel. He underlined that around 80% of  Medtronic plc (NYSE:MDT)'s supply chain and over 90% of R&D are based in the US.

15 States with the Best Healthcare in the US

Martha pointed to growth as a buffer with a 78% revenue jump in cardiac ablation alongside strength in pacemakers, surgical, and spine businesses.

He also said the medtech firm put in $2 billion in acquisitions over the past fiscal year and invests $5 billion to $6 billion annually in innovation.

Medtronic plc (NYSE:MDT) is a medical technology compa

Fuente original: Yahoo Finance (https://finance.yahoo.com/economy/policy/articles/medtronic-plc-mdt-ceo-discloses-153207076.html)